Challenges and new discoveries in the treatment of leishmaniasis
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Herwaldt, B. L. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10178-2 · Cited by 1,229
Human Leishmaniasis: Clinical, Diagnostic, and Chemotherapeutic Developments in the Last 10 Years
Berman, J. D. (1997) · Clinical Infectious Diseases · doi:10.1093/clind/24.4.684 · Cited by 806
Oral Miltefosine for Indian Visceral Leishmaniasis
Sundar, S., Jha, T. K., Thakur, C. P., Engel, J., Sindermann, H., Fischer, C., Junge, K., Bryceson, A., & Berman, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021556 · Cited by 779
Miltefosine, an Oral Agent, for the Treatment of Indian Visceral Leishmaniasis
Jha, T. K., Sundar, S., Thakur, C. P., Bachmann, P., Karbwang, J., Fischer, C., Voss, A., & Berman, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412403 · Cited by 468
Croft, S., & Yardley, V. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396258 · Cited by 380
Treatment of Visceral Leishmaniasis with Pentavalent Antimony and Interferon Gamma
Badaro, R., Falcoff, E., Badaro, F. S., Carvalho, E. M., Pedral-Sampaio, D., Barral, A., Carvalho, J. S., Barral-Netto, M., Brandely, M., Silva, L., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001043220104 · Cited by 310
Chunge, C. N., Owate, J., Pamba, H. O., & Donno, L. (1990) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(90)90263-e · Cited by 175
Bowden, R. A., Cays, M., Gooley, T., Mamelok, R. D., & van Burik, J.-A. (1996) · Journal of Infectious Diseases · doi:10.1093/infdis/173.5.1208 · Cited by 117
Liposomal Amphotericin B (AmBisome) in the Treatment of Complicated Kala-Azar Under Field Conditions
Seaman, J., Boer, C., Wilkinson, R. J., de Jong, J., Wilde, E., Sondorp, E., & Davidson, R. N. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.1.188 · Cited by 109
Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial.
Sn, J., Singh, N. K., & Tk, J. (1991) · PubMed · Cited by 85
Cited by
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Natural products to drugs: natural product derived compounds in clinical trials
Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 491
Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions
Haldar, A. K., Sen, P., & Roy, S. (2011) · Molecular Biology International · doi:10.4061/2011/571242 · Cited by 408
Antileishmanial and antifungal activity of plants used in traditional medicine in Brazil
Braga, F. G., Bouzada, M. L. M., Fabri, R. L., de O. Matos, M., Moreira, F. O., Scio, E., & Coimbra, E. S. (2007) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.12.006 · Cited by 305
Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles☆
DATE, A., JOSHI, M., & PATRAVALE, V (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.009 · Cited by 293
Biofabrication of nanoparticles: sources, synthesis, and biomedical applications
Kulkarni, D., Sherkar, R., Shirsathe, C., Sonwane, R., Varpe, N., Shelke, S., More, M. P., Pardeshi, S. R., Dhaneshwar, G., Junnuthula, V., et al. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1159193 · Cited by 267
Grover, A., Katiyar, S. P., Jeyakanthan, J., Dubey, V. K., & Sundar, D. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-s7-s20 · Cited by 52
“donovani has developed drug-resistance and toxicity towards available drugs [3,4].”
Background
Metadata
- Authors
- Singh, S., & Sivakumar, R.
- Venue
- Journal of Infection and Chemotherapy
- Publisher
- Elsevier BV
- Published
- 2004
- Volume
- 10
- Issue
- 6
- Pages
- 307-315
- ISSN
- 1341-321X (ISSN-L)
- OpenAlex
- W1981968564
- Cited by
- 293
- References
- 12
- FWCI
- 15.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.